1. Home
  2. NXL vs ADIL Comparison

NXL vs ADIL Comparison

Compare NXL & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

N/A

Current Price

$6.73

Market Cap

7.5M

Sector

Health Care

ML Signal

N/A

Logo Adial Pharmaceuticals Inc

ADIL

Adial Pharmaceuticals Inc

N/A

Current Price

$5.88

Market Cap

7.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NXL
ADIL
Founded
2010
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
7.3M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
NXL
ADIL
Price
$6.73
$5.88
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$37.50
AVG Volume (30 Days)
139.6K
75.4K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
39.76
N/A
EPS
N/A
N/A
Revenue
$301,647.00
N/A
Revenue This Year
$15.52
N/A
Revenue Next Year
$100.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
78.78
N/A
52 Week Low
$0.22
$0.13
52 Week High
$7.69
$6.41

Technical Indicators

Market Signals
Indicator
NXL
ADIL
Relative Strength Index (RSI) 96.86 65.61
Support Level $0.44 $1.63
Resistance Level N/A $6.41
Average True Range (ATR) 0.18 0.65
MACD 0.69 -0.01
Stochastic Oscillator 92.77 79.73

Price Performance

Historical Comparison
NXL
ADIL

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.

About ADIL Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.

Share on Social Networks: